Companies in #Solid tumors with RAF/MEK pathway alterations
Found 1 company operating in this sector.
Verastem Oncology is a commercial-stage biopharmaceutical company (NASDAQ: VSTM) developing medicines to improve the lives of patients with cancer, with a focus on RAS/MAPK pathway-driven tumors and hematologic cancers. Lead marketed product is Avmapki Fakzynja Co-Pack (avutometinib + defactinib) for KRAS-mutated recurrent low-grade serous ovarian cancer.